Potent in vitro Inhibition of CYP3A4 and P-Glycoprotein by Rhodiola rosea

Planta Medica

Volumn 76, Issue 4, 2010, Pages 331-338

  Hellum, Bent H ^a   Tosse, Anita ^b   Hoybakk, Kathrine ^a   Thomsen, Mette ^b   Rohloff, Jens ^c   Georg Nilsen, Odd ^a  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b NORWEGIAN INSTITUTE OF BIOECONOMY RESEARCH   (Norway)

^c NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

Crassulaceae; CYP3A4; Cytochrome P450; Inhibition; Pglycoprotein; Rhodiola rosea

Indexed keywords

CINNAMYL ALCOHOL; COMPLEMENTARY DNA; CYTOCHROME P450 3A4; DIGOXIN; FLUOXETINE; GLYCOPROTEIN P; KETOCONAZOLE; RHODIOLA ROSEA EXTRACT; SALIDROSIDE; TYROSOL; VERAPAMIL;

ARTICLE; BACULOVIRUS EXPRESSION SYSTEM; CELL STRAIN CACO 2; CONTROLLED STUDY; DRY WEIGHT; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HYPERICUM PERFORATUM; IC 50; IN VITRO STUDY; MOLECULAR CLONING; PROTEIN TRANSPORT; SCINTILLATION COUNTING;

BACULOVIRIDAE; CACO-2 CELLS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP3A; DIGOXIN; DNA, COMPLEMENTARY; HERB-DRUG INTERACTIONS; HUMANS; INHIBITORY CONCENTRATION 50; KETOCONAZOLE; P-GLYCOPROTEIN; PLANT EXTRACTS; RHODIOLA; STRUCTURE-ACTIVITY RELATIONSHIP; TESTOSTERONE; VERAPAMIL;

CRASSULACEAE; RHODIOLA ROSEA;

EID: 77749308365     PISSN: 00320943     EISSN: 14390221     Source Type: Journal    
DOI: 10.1055/s-0029-1186153     Document Type: Article

References (41)

1. Ming D S., Hillhouse B J., Guns E S., Eberding A, Xie S, Vimalanathan S, Towers G H. Bioactive compounds from Rhodiola rosea (Crassulaceae). Phytother Res 2005 19 740-743
2. Spasov A A., Wikman G K., Mandrikov V B., Mironova I A., Neumoin V V. A double-blind, placebo-controlled pilot study of the stimulating and adaptogenic effect of Rhodiola rosea SHR-5 extract on the fatigue of students caused by stress during an examination period with a repeated low-dose regimen. Phytomedicine 2000 7 85-89
3. Mattioli L, Perfumi M. Rhodiola rosea L. extract reduces stress- and CRF-induced anorexia in rats. J Psychopharmacol 2007 21 742-750
4. Brown R P., Gerbarg P L., Ramazanov Z. Rhodiola rosea. A phytochemical overview. Herbalgram 2002 56 40-52
5. Bystritsky A, Kerwin L, Feusner J D. A pilot study of Rhodiola rosea (Rhodax) for generalized anxiety disorder (GAD). J Altern Complement Med 2008 14 175-180
6. Roland P D., Amundstuen L. [Roseroot statements and documentation]. Tidsskr Nor Laegeforen 2007 127 882-883
7. Scott I M., Leduc R I., Burt A J., Marles R J., Arnason J T., Foster B C. The inhibition of human cytochrome P450 by ethanol extracts of North American botanicals. Pharm Biol 2006 44 315-327
8. Kucinskaite A, Poblocka-Olech L, Krauze-Baranowska M, Sznitowska M, Savickas A, Briedis V. Evaluation of biologically active compounds in roots and rhizomes of Rhodiola rosea L. cultivated in Lithuania. Medicina (Kaunas) 2007 43 487-494
9. Southwell I A., Bourke C A. Seasonal variation in hypericin content of Hypericum perforatum L. (St. John's wort). Phytochemistry 2001 56 437-441
10. de los Reyes G C., Koda R T. Determining hyperforin and hypericin content in eight brands of St. John's wort. Am J Health Syst Pharm 2002 59 545-547
11. Ortiz de Montellano P R. Cytochrome P450. Structure, mechanism and biochemistry. New York Kluwer Academic/Plenum Publishers 2005
12. Hellum B H., Hu Z, Nilsen O G. The induction of CYP1A2, CYP2D6 and CYP3A4 by six trade herbal products in cultured primary human hepatocytes. Basic Clin Pharmacol Toxicol 2007 100 23-30
13. Gaudineau C, Beckerman R, Welbourn S, Auclair K. Inhibition of human P450 enzymes by multiple constituents of the Ginkgo biloba extract. Biochem Biophys Res Commun 2004 318 1072-1078
14. Ameer B, Weintraub R A. Drug interactions with grapefruit juice. Clin Pharmacokinet 1997 33 103-121
15. Gurley B J., Gardner S F., Hubbard M A., Williams D K., Gentry W B., Khan I A., Shah A. In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. Clin Pharmacol Ther 2005 77 415-426
16. Al-Shawi M K., Omote H. The remarkable transport mechanism of P-glycoprotein: a multidrug transporter. J Bioenerg Biomembr 2005 37 489-496
17. Flanagan D. Understanding the grapefruit-drug interaction. Gen Dent 2005 53 282-285
18. Elameen A, Klemsdal S S., Dragland S, Fjellheim S, Rognli O A. Genetic diversity in a germplasm collection of roseroot (Rhodiola rosea) in Norway studied by AFLP. Biochem Syst Ecol 2008 36 706-715
19. Hellum B H., Nilsen O G. In vitro inhibition of CYP3A4 metabolism and P-glycoprotein-mediated transport by trade herbal products. Basic Clin Pharmacol Toxicol 2008 102 466-475
20. Engdal S, Nilsen O G. In vitro inhibition of CYP3A4 by herbal remedies frequently used by cancer patients. Phytother Res 2009 23 906-912
21. Brodie R, Hill H. Validation issues arising from the new FDA guidance for industry on bioanalytical method validation. Chromatographia 2002 55 S91-S94
22. Engdal S, Nilsen O G. Inhibition of P-glycoprotein in Caco-2 cells: effects of herbal remedies frequently used by cancer patients. Xenobiotica 2008 38 559-573
23. Oppiah-Opong R, Commandeur J N., Axson C, Vermeulen N P. Interactions between cytochromes P450, glutathione S-transferases and Ghanaian medicinal plants. Food Chem Toxicol 2008 46 3598-3603
24. Liu K H., Kim M J., Jeon B H., Shon J H., Cha I J., Cho K H., Lee S S., Shin J G. Inhibition of human cytochrome P450 isoforms and NADPH-CYP reductase in vitro by 15 herbal medicines, including Epimedii herba. J Clin Pharm Ther 2006 31 83-91
25. Zou L, Harkey M R., Henderson G L. Effects of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic activity. Life Sci 2002 71 1579-1589
26. Eagling V A., Wiltshire H, Whitcombe I W., Back D J. CYP3A4-mediated hepatic metabolism of the HIV-1 protease inhibitor saquinavir in vitro. Xenobiotica 2002 32 1-17
27. McConn D J., Lin Y S., Allen K, Kunze K L., Thummel K E. Differences in the inhibition of cytochromes P450 3A4 and 3A5 by metabolite-inhibitor complex-forming drugs. Drug Metab Dispos 2004 32 1083-1091
28. Ridtitid W, Wongnawa M, Mahatthanatrakul W, Raungsri N, Sunbhanich M. Ketoconazole increases plasma concentrations of antimalarial mefloquine in healthy human volunteers. J Clin Pharm Ther 2005 30 285-290
29. Rengelshausen J, Banfield M, Riedel K D., Burhenne J, Weiss J, Thomsen T, Walter-Sack I, Haefeli W E., Mikus G. Opposite effects of short-term and long-term St. John's wort intake on voriconazole pharmacokinetics. Clin Pharmacol Ther 2005 78 25-33
30. Yoshida N, Takagi A, Kitazawa H, Kawakami J, Adachi I. Inhibition of P-glycoprotein-mediated transport by extracts of and monoterpenoids contained in Zanthoxyli fructus. Toxicol Appl Pharmacol 2005 209 167-173
31. Keogh J P., Kunta J R. Development, validation and utility of an in vitro technique for assessment of potential clinical drug-drug interactions involving P-glycoprotein. Eur J Pharm Sci 2006 27 543-554
32. Pauli-Magnus C, Rekersbrink S, Klotz U, Fromm M F. Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein. Naunyn Schmiedebergs Arch Pharmacol 2001 364 551-557
33. Igel S, Drescher S, Murdter T, Hofmann U, Heinkele G, Tegude H, Glaeser H, Brenner S S., Somogyi A A., Omari T, Schafer C, Eichelbaum M, Fromm M F. Increased absorption of digoxin from the human jejunum due to inhibition of intestinal transporter-mediated efflux. Clin Pharmacokinet 2007 46 777-785
34. Kiley C A., Cragin D J., Roth B J. Omeprazole-associated digoxin toxicity. South Med J 2007 100 400-402
35. Rautio J, Humphreys J E., Webster L O., Balakrishnan A, Keogh J P., Kunta J R., Serabjit-Singh C J., Polli J W. In vitro P-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates. Drug Metab Dispos 2006 34 786-792
36. Fromm M F., Kim R B., Stein C M., Wilkinson G R., Roden D M. Inhibition of P-glycoprotein-mediated drug transport: a unifying mechanism to explain the interaction between digoxin and quinidine. Circulation 1999 99 552-557
37. Artursson P, Palm K, Luthman K. Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv Drug Deliv Rev 2001 46 27-43 (Pubitemid 33653412)
38. Collett A, Tanianis-Hughes J, Carlson G L., Harwood M D., Warhurst G. Comparison of P-glycoprotein-mediated drug-digoxin interactions in Caco-2 with human and rodent intestine: relevance to in vivo prediction. Eur J Pharm Sci 2005 26 386-393
39. Lowes S, Cavet M E., Simmons N L. Evidence for a non-MDR1 component in digoxin secretion by human intestinal Caco-2 epithelial layers. Eur J Pharmacol 2003 458 49-56
40. Hillhouse B J., Ming D S., French C J., Towers N G. H. Acetylcholine esterase inhibitors in Rhodiola rosea. Pharm Biol 2004 42 68-72
41. Majewska A, Hoser G, Furmanowa M, Urbanska N, Pietrosiuk A, Zobel A, Kuras M. Antiproliferative and antimitotic effect, S phase accumulation and induction of apoptosis and necrosis after treatment of extract from Rhodiola rosea rhizomes on HL-60 cells. J Ethnopharmacol 2006 103 43-52